Cardiovascular Therapeutics

About this Journal

Aims and scope

Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged.

Subject areas include (but are by no means limited to):

  • Acute coronary syndrome
  • Arrhythmias
  • Atherosclerosis
  • Basic cardiac electrophysiology
  • Cardiac catheterization
  • Cardiac remodeling
  • Coagulation and thrombosis
  • Diabetic cardiovascular disease
  • Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF)
  • Hyperlipidemia
  • Hypertension
  • Ischemic heart disease
  • Vascular biology
  • Ventricular assist devices
  • Molecular cardio-biology
  • Myocardial regeneration
  • Lipoprotein metabolism
  • Radial artery access
  • Percutaneous coronary intervention
  • Transcatheter aortic and mitral valve replacement

    The Wiley Hindawi Partnership

    This journal is published by Hindawi as part of a publishing collaboration with John Wiley & Sons, Inc. It is a fully Open Access journal produced under the Hindawi and Wiley brands.

    Bibliographic information

    ISSN: 1755-5914 (Print)
    ISSN: 1755-5922 (Online)
    DOI: 10.1155/4702

    Archival content

    Content published prior to 2019 is hosted on the Wiley Online Library.

      Contact

      Editorial enquiries should be directed to help@hindawi.com

        Cardiovascular Therapeutics
        Publishing Collaboration
        More info
        Wiley Hindawi logo
         Journal metrics
        Acceptance rate14%
        Submission to final decision58 days
        Acceptance to publication44 days
        CiteScore2.180
        Impact Factor2.538
         Submit

        We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.